585Ofranergene obadenovec (VB-111) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single-center, single-arm phase II trialdoi:10.1136/jitc-2023-SITC2023.0585ImmunotherapyTumor MicroenvironmentGastrointestinal NeoplasmsLiver Neoplasms...
Ofranergene obadenovec, also known as VB-111, is a viral-based cancer therapy that has a dual mechanism of action: anti-angiogenesis/vascular disruption and induction of tumor directed intra-tumor immune response, such as seen in viral immune-oncology (Fig. 1). VB-111 has three main compo...
PurposeTo evaluate the addition of ofranergene obadenovec (ofra-vec, VB-111), a novel gene-based anticancer targeted therapy, to once a week paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC).MethodsThis placebo-controlled, double-blind, phase III trial (ClinicalTrials...
Background: Ofranergene obadenovec (ofra-vec, VB-111) is a nonreplicating adenoviral vector with a murine pro-endothelin 1 (PPE-1-3X) promoter and pro-apoptotic Fas-tumor necrosis factor receptor 1 (TNFR1) chimeric transgene thought to have a dual mechanism of action: vascular disruption ...
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effectVB-111Gene therapyAnti-angiogenicPlatinum-resistant ovarian cancerImmunotherapeutic
Introduction: Ofranergene Obadenovec (VB-111) is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. Improved responses seen among patients experiencing post treatment fever ...